UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000052306
Receipt number R000059577
Scientific Title Effects of a Test Food for Improvement of Skin Function.
Date of disclosure of the study information 2023/09/26
Last modified on 2024/04/26 10:20:20

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effects of a Test Food for Improvement of Skin Function.

Acronym

Effects of a Test Food for Improvement of Skin Function.

Scientific Title

Effects of a Test Food for Improvement of Skin Function.

Scientific Title:Acronym

Effects of a Test Food for Improvement of Skin Function.

Region

Japan


Condition

Condition

No

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

This study aims to examine effects of a test food on improvement of skin function.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Skin color ( Color-difference measurement )
(Week 0, Week 4, Week 8)

Key secondary outcomes

1) Image analysis by VISIA (1)
2) Skin blood flow measurement (1)
3) Measurement of glycative stress markers (AGEs) (1)
4) Observation for skin condition by dermatologists (Texture, Skin quality) (1)
5) Visual Analogue Scale (1)
6) The Japanese version of the Pittsburgh Sleep Quality Index (1)
7) Adverse events and side effects (2)

(1): Week 0, Week 4, Week 8
(2): Week 4, Week 8


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

3

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Oral intake of the test food A (Dissolve 1 packet in 100-150mL of water and intaking one time a day for 8 weeks).

Interventions/Control_2

Oral intake of the test food B (Dissolve 1 packet in 100-150mL of water and intaking one time a day for 8 weeks).

Interventions/Control_3

Oral intake of the placebo food (Dissolve 1 packet in 100-150mL of water and intaking one time a day for 8 weeks).

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

35 years-old <=

Age-upper limit

55 years-old >

Gender

Female

Key inclusion criteria

1) Healthy Japanese females aged 35-54 years.
2) Individuals who are healthy and have no chronic physical disease including skin disease.
3) Individuals who are aware of or concerned about dullness of their skin.

Key exclusion criteria

1) Individuals who have a past or present history of serious illness.
2) Individuals who have wounds or inflammation in the evaluation site.
3) Individuals who are sensitive to the test food.
4) Individuals who have had a habit of continuously ingesting drugs, quasi-drugs, health functional foods, health foods, or supplements that claim whitening/skin improvement effects within 3 months before the start of the test, or who plan to use them during the test period.
5) Individuals who have used cosmetics that claim whitening effects within 3 months before the start of the test, or who plan to use them during the test period.
6) Individuals who are or are possibly pregnant, or are lactating.
7) Individuals who excessively take alcohol (expressed in an amount of alcohol: over 60g/day).
8) Individuals who are a smoker.
9) Individuals with possible changes of life style during the test period.
10) Individuals who will develop seasonal allergy symptoms like hay fever and be to suffer from worsening eyes and nose symptoms or use anti-allergic drugs during the test period.
11) Individuals who will get sunburned during the test period.
12) Individuals who had been conducted an operation or beauty treatment on the evaluation area within 6 months before the start of the test.
13) Individuals who participated in other clinical studies in the past 3 months.
14) Individuals judged inappropriate for the study by the principal.

Target sample size

60


Research contact person

Name of lead principal investigator

1st name Atsushi
Middle name
Last name Nakajima

Organization

Ueno-Asagao Clinic

Division name

Head

Zip code

110-0015

Address

6F Kairaku Building 2-7-5 Higashiueno Taito-ku Tokyo 110-0015, JAPAN

TEL

+81-3-6240-1162

Email

info@ueno-asagao.clinic


Public contact

Name of contact person

1st name Ryoma
Middle name
Last name Shimizu

Organization

TES Holdings Co., Ltd.

Division name

Administrative Department of Clinical Trials

Zip code

110-0015

Address

6F Kairaku Building 2-7-5 Higashiueno Taito-ku Tokyo 110-0015, JAPAN

TEL

+81-3-6801-8480

Homepage URL


Email

r.shimizu@tes-h.co.jp


Sponsor or person

Institute

TES Holdings Co., Ltd.

Institute

Department

Personal name



Funding Source

Organization

Morinaga Milk Industry Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ueno-Asagao Clinic Ethical Review Committee

Address

6F Kairaku Building 2-7-5 Higashiueno Taito-ku Tokyo 110-0015, JAPAN

Tel

+81-3-6240-1162

Email

jimukyoku@tes-h.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 09 Month 26 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2023 Year 08 Month 30 Day

Date of IRB

2023 Year 08 Month 31 Day

Anticipated trial start date

2023 Year 10 Month 07 Day

Last follow-up date

2023 Year 12 Month 09 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2023 Year 09 Month 25 Day

Last modified on

2024 Year 04 Month 26 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000059577